Notice of Special Interest (NOSI): Availability of Emergency Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs
First Available Due Date:
December 17, 2020
June 02, 2021
PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
National Center for Advancing Translational Sciences (NCATS)
The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts.
NCATS is soliciting applications for Administrative Supplements (through PA-20-272) from current Clinical and Translational Science Award (CTSA) UL1 component award recipients from these FOAs:
- PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional)
- PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)
- PAR-15-304 Clinical and Translational Science Award (U54 Clinical Trial Optional)
- RFA-TR-14-009 Clinical and Translational Science Award (U54 Clinical Trial Optional)
NCATS expects to issue 2-9 awards (anticipated to be $30,000 to $60,000 Direct Costs) for provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data.
Application and Submission Information
Applications in response to this NOSI must be submitted to the following target opportunity or subsequently reissued equivalents. Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissue of this announcement through the expiration date of this notice and designate “NOT-TR-21-011” (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form as directed below.
- PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional), which is intended to provide additional funds for NIH grantees for work that falls within the scope of their active grant.
When developing applications in response to this NOSI, all instructions in the SF424 (R&R) Application Guide and in the target funding opportunity announcement (PA-20-272) must be followed, with the following additions:
- Applications will be accepted immediately and on a rolling basis through June 1, 2021 by 5:00 PM local time of the applicant organization. This NOSI expires on June 2, 2021. An application submitted in response to this NOSI that is received on June 2, 2021 or later, will be withdrawn. Applications will be considered for funding in FY21 pending: award timelines, availability of funds, and programmatic priority.
- IMPORTANT: For funding consideration, all applicants must designate“NOT-TR-21-011” (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form. Applications without this information in Box 4b will not be considered for this initiative.
- The Research Strategy section of the application is limited to 6 pages. Address assurances that the proposed project can be performed as described under the current Public Health Emergency circumstances.
- Recipients may apply for work that is related to the funded project, regardless of the time remaining on the current project. Grants currently in a no-cost extension are eligible to apply.
- The project period will generally be limited to 1 year.
- Follow the FOA Instructions for Electronic Application Submission through the NIH ASSIST system, an institutional system-to-system (S2S) solution, or Grants.gov workspace.
- Administrative supplement applications to PA-20-272 must use the application form package with the Competition ID that contains “FORMS-E-ADMINSUPP”. In addition, the process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.
- Applications must specifically address issues of potential biohazards in the Research Strategy, and all research must be conducted in compliance with the health and safety requirements found in the NIH Grants Policy Statement.
- Applications will be subject to the NIH guidance posted on the following website: https://grants.nih.gov/policy/natural-disasters/corona-virus.htm
- Funds awarded using appropriations provided by the Coronavirus Aid, Relief, and Economic Security (CARES) Act will be issued in unique subaccounts in the HHS Payment Management System, and will require separate financial reporting from any other funds awarded.
Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact the Grants Management Specialist on their active award to determine eligibility and the Program Officer on their active award to discuss the proposed project in the context of the parent award.
Applications that do not meet the requirements specified in this NOSI will be withdrawn from consideration for this initiative.
Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:
Please contact the program officer on the active award.